Yükleniyor... / Loading...
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Bu çalışma, ROS1 yeniden düzenlenmesi veya MET geni değişiklikleri (exon 14 mutasyonu ya da amplifikasyon) olan küçük hücreli dışı akciğer kanseri (non-small cell lung cancer) hastalarında Crizotinib tedavisini incelemektedir. Evre IV veya tedavisi mümkün olmayan skuamöz dışı akciğer kanseri olan, 18 yaş ve üzeri hastalar katılabilmiştir. Çalışma Faz 2 aşamasında yürütülmüş ve tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement (cohort 1) or MET-activating mutation (exon 14) (cohort 2) or MET-amplification (cohort 3) tested in either plasma or tissue, as applicable * 18 years of age or older. * Measurable disease as per RECIST v1.1. * Adequate hematologic and organ function within 7 days of the proposed start date of treatment and adequate cardiac function within 28 days of the proposed start date of treatment * Life expectancy \>12 weeks. * Have the ability to understand and the willingness to sign a written informed consent document * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 * No contraindication to Crizotinib therapy * Able to swallow and retain oral medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. * No pregnant * Agree to use methods (as agreed upon by the study doctor and participant) before the study and for at least 120 days after the last dose of study drug to prevent pregnancy Exclusion Criteria: * Symptomatic untreated brain metastases. * Had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g. targeted therapy or antibodies) within 4 weeks or radiotherapy within 2 weeks prior to the proposed first dose of study treatment. * Adverse events attributed to prior anti-cancer therapy \> Grade 1 if clinically relevant. * Receiving medications or substances known to be strong inhibitors or inducers of CYP3A4. * Any known intolerance to agents structurally similar to crizotinib. * Congenital long QT syndrome or persistent corrected QT interval by Fredericia formula (QTcF) ≥ 500 msec. * Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues